➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Boehringer Ingelheim
Merck
Medtronic
AstraZeneca

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LAPATINIB DITOSYLATE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Lapatinib Ditosylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00085020 ↗ GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu Completed National Cancer Institute (NCI) Phase 1 2004-03-01 RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving GW572016 with trastuzumab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given together with trastuzumab in treating patients with metastatic breast cancer that overexpresses HER2/neu.
NCT00085020 ↗ GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu Completed Jonsson Comprehensive Cancer Center Phase 1 2004-03-01 RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving GW572016 with trastuzumab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given together with trastuzumab in treating patients with metastatic breast cancer that overexpresses HER2/neu.
NCT00095563 ↗ Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed National Cancer Institute (NCI) Phase 2 2004-09-01 Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent and/or metastatic adenoid cystic cancer or other salivary gland cancers. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
NCT00095667 ↗ Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 2004-11-01 Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent or metastatic prostate cancer.
NCT00095940 ↗ Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed National Cancer Institute (NCI) Phase 1/Phase 2 2004-10-01 This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lapatinib Ditosylate

Condition Name

Condition Name for Lapatinib Ditosylate
Intervention Trials
Breast Cancer 20
Stage IV Breast Cancer 11
Stage IIIC Breast Cancer 7
HER2-positive Breast Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lapatinib Ditosylate
Intervention Trials
Breast Neoplasms 38
Carcinoma 13
Breast Neoplasms, Male 7
Neoplasm Metastasis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lapatinib Ditosylate

Trials by Country

Trials by Country for Lapatinib Ditosylate
Location Trials
United States 268
Canada 16
Germany 13
Italy 8
Korea, Republic of 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lapatinib Ditosylate
Location Trials
California 18
Pennsylvania 11
New York 11
Ohio 11
North Carolina 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lapatinib Ditosylate

Clinical Trial Phase

Clinical Trial Phase for Lapatinib Ditosylate
Clinical Trial Phase Trials
Phase 3 5
Phase 2/Phase 3 1
Phase 2 32
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lapatinib Ditosylate
Clinical Trial Phase Trials
Completed 38
Active, not recruiting 11
Terminated 7
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lapatinib Ditosylate

Sponsor Name

Sponsor Name for Lapatinib Ditosylate
Sponsor Trials
National Cancer Institute (NCI) 47
GlaxoSmithKline 8
European Organisation for Research and Treatment of Cancer - EORTC 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lapatinib Ditosylate
Sponsor Trials
NIH 47
Other 45
Industry 13
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
McKesson
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.